A Low Containment CCHFV Entry Screening Platform Identifies Compounds with Antiviral Activity against Authentic CCHFV

Viruses are not living things in the traditional sense; they are more like microscopic packages of genetic instructions that cannot survive or reproduce on their own. To make more of themselves, they must invade a living cell, hijack its machinery, and force it to build new virus particles. The first and most critical step in this invasion is entry. A virus must first attach to the surface of a cell and then fuse its outer shell with the cell's membrane to slip inside. For many dangerous viruses, this entry process is driven by specific proteins on the virus surface that act like keys, unlocking the cell door. If scientists can find a substance that jams these keys or blocks the door, they can stop the infection before it even begins. This is a promising strategy for fighting viral diseases, but it becomes incredibly difficult when the virus in question is so dangerous that it can only be studied in the most secure laboratories on Earth.

Crimean-Congo hemorrhagic fever virus, or CCHFV, is one such dangerous pathogen. It is carried by ticks and can cause severe, often fatal illness in humans. Because it is so hazardous, any research involving the actual, live virus must be conducted in a Biosafety Level 4 facility, a high-security environment where researchers wear full-body protective suits and work inside sealed containment chambers. These strict safety rules mean that only a handful of laboratories worldwide can study the virus, and the work is slow, expensive, and limited in scale. This creates a major bottleneck for finding new medicines. Scientists need a way to test potential drugs against the virus's entry mechanism without having to use the live, dangerous virus for every single experiment. They need a safe, lower-security model that mimics the critical first steps of the infection.

A team of researchers has developed just such a model and used it to find two existing drugs that might stop CCHFV. They created a safe, non-infectious version of the virus that carries the entry proteins of CCHFV on its surface but lacks the ability to replicate or cause disease. This "pseudotype" virus can be studied in standard, lower-security laboratories. Using this system, the researchers screened a library of 186 different chemical compounds to see which ones could block the virus from entering cells. They identified two candidates: a drug called eltrombopag olamine, which is currently used to treat low platelet counts, and quercetin, a natural compound found in many fruits and vegetables. Both substances successfully stopped the safe, fake virus from entering cells, and importantly, they did not kill the cells themselves.

The researchers then wanted to know exactly when these drugs worked during the infection process. They performed a series of timed experiments, adding the drugs at different moments relative to when the virus touched the cells. They found that both compounds were most effective when present during the initial attachment of the virus and the very early stages of entry. This timing suggests the drugs interfere with the virus's ability to fuse with the cell membrane, a process that normally happens after the virus is inside a small, acidic pocket within the cell. To confirm this, the team tested the drugs in a separate assay that directly measured the ability of the viral proteins to fuse two cells together. Both eltrombopag olamine and quercetin significantly reduced this fusion activity, particularly under the acidic conditions that trigger the process. Computer modeling further suggested that these drugs likely bind to specific regions of the viral proteins involved in this fusion, potentially preventing the structural changes needed for the virus to enter.

The most critical test, however, was whether these findings held up against the real, dangerous virus. The researchers moved their work to a high-security Biosafety Level 4 laboratory to test the compounds against authentic, live CCHFV. They used a modified version of the virus that glows green when it successfully infects a cell. In these high-containment experiments, both eltrombopag olamine and quercetin again showed the ability to stop the virus, reducing the number of infected cells in a dose-dependent manner. While the drugs were less potent against the real virus than they were against the safe model, the results confirmed that the lower-security screening method successfully identified compounds with genuine antiviral activity. The researchers also tested these drugs against a different virus, Rift Valley fever virus, and found that the inhibition was much weaker, suggesting the compounds might have a specific effect on the entry mechanisms of CCHFV rather than a general effect on all viruses.

This study demonstrates a practical path forward for discovering treatments for the world's most dangerous viruses. By using a safe, surrogate system to narrow down the list of potential drugs, scientists can identify the most promising candidates without needing to use the live virus for every initial test. Once a few strong candidates are found, they can be validated in the high-security labs where the real virus is handled. The two compounds identified in this work, eltrombopag olamine and quercetin, are not yet ready to be used as cures; they are effective at concentrations that are relatively high, and more research is needed to understand exactly how they work and to improve their potency. However, they serve as proof that this screening strategy works. They provide a starting point for further investigation, offering a way to explore the vulnerabilities of the virus's entry process and potentially leading to the development of effective treatments for a disease that currently has no approved antiviral therapy.